Introduction
Extracellular acidosis is commonly observed in solid cancers. Pyruvate is converted to lactic acid by lactate dehydrogenase (LDH) under anaerobic conditions; in cancer cells, the Warburg effect, in which pyruvic acid is converted to lactic acid under aerobic conditions, also occurs [
1,
2]. Excessive production of lactic acid results in its extracellular release, which in turn results in extracellular acidosis [
3]. The low pH of the area surrounding the tumor is known to promote metastasis and proliferation by inducing an aggressive phenotype, as well as by suppressing immune cell activity [
4]. Therefore, targeting extracellular acidosis to suppress cancer cell activity and activate immune cells is essential for cancer treatment.
The immune checkpoint proteins programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) are mainly expressed on immune cells and cancer cells, respectively [
5]. When bound by PD-L1 expressed on cancer cells, PD-1 of immune cells is exhausted and cannot effectively target cancer cells [
6]. PD-L1 expression is increased in cancer cells; higher PD-L1 expression in cancer patients is correlated with significantly lower overall and recurrence-free survival. Thus, targeting the increased expression of PD-L1 is important for immunotherapy [
7,
8].
When phosphorylated, the transcription factor signal transducer and activator of transcription 3 (STAT3) forms homo or heterodimers, and translocates from the cytoplasm to the nucleus to induce the expression of target genes [
9]. The increased activation of STAT3 in cancer cells results in the expression of various oncogenes that induce tumor metastasis, stemness, proliferation, angiogenesis, and anti-apoptosis [
10]. In addition, STAT3 induces the expression of PD-L1, which has been linked to immunosuppression [
11]. Therefore, activating STAT3 by suppressing immune exhaustion through inhibition of PD-L1 expression may be a viable strategy for cancer treatment.
Recent studies have reported that the expression of PD-L1 is increased by lactate in Lewis lung carcinoma and melanoma cells; tumor growth was also significantly reduced following treatment with both sodium bicarbonate (NaHCO
3) and a PD-L1 inhibitor [
12‐
14]. However, the relationship between tumor acidosis and PD-L1 in breast cancer, and the detailed mechanisms by which PD-L1 is increased by acidosis, are not well understood. The aim of this study was to identify the cause of the increased PD-L1 expression, and to suggest novel methods to suppress PD-L1 expression in breast cancer cells.
Although many drugs have been developed to inhibit PD-L1, it is important to understand the underlying cause of increased PD-L1 expression in cancer cells [
15‐
17]. We found that extracellular acidosis increased PD-L1 expression in MDA-MB-231 cells. In addition, tyrosine 705 of STAT3 was significantly phosphorylated by acidification, and the expression of PD-L1 was increased by phosphorylation of STAT3. The results of this study suggest that targeting tumor acidosis could prevent immune exhaustion in breast cancer cells.
Materials and methods
Reagents and antibodies
Sodium bicarbonate (NaHCO3), lactic acid, sodium lactate and sodium oxamate were obtained from Sigma Aldrich (St. Louis, MO, USA). The antibodies used in this study were as follows: anti-PD-L1 (Abcam, Cambridge, UK); anti-LDH-A (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-pY701-STAT1, anti-STAT1, anti-pY705-STAT3, anti-pS727-STAT3, anti-STAT3 and anti-β-actin (Cell Signaling Technology, Danvers, MA, USA); and anti-HIF-1α (Abbkine, Wuhan, China).
Cell culture and culture conditions
The human breast cancer cell line MDA-MB-231 was obtained from the American Type Culture Collection (Manassas, VA, USA), and Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and penicillin/streptomycin were obtained from Capricorn Scientific (Ebsdorfergrund, Germany). MDA-MB-231 cells were maintained in DMEM with 10% FBS and 1% penicillin/streptomycin and incubated in a humidified incubator (Vision Science, Seoul, Republic of Korea) containing 5% CO2 at 37 °C.
pH regulation and measure
To mimic extracellular acidosis, 1 M HCl and lactic acid were used as described previously [
18]. In addition, 1 M NaOH and NaHCO
3 were used to neutralize or buffer acidic pH. The pH-adjusted culture medium was stabilized in a 5% CO
2 incubator prior to treatment. The pH of cell culture media was measured using a pH meter (Mettler Toledo, Columbus, OH, USA).
Conditioned medium
MDA-MB-231 cells were cultured in normoxia (21% O2 and 5% CO2) or hypoxia (2% O2 and 5% CO2) with/without oxamate for 36 h, and normoxic conditioned medium (NCM) and hypoxic conditioned medium (HCM) were collected. Heat-inactivated HCM was obtained by boiling HCM for 20 min at 100 °C to degrade secretory proteins in the conditioned medium, and the pH neutralized HCM was obtatined by adding 1 M NaOH to neutralize acidified HCM.
Western blotting
MDA-MB-231 cells were lysed using 1% Triton X-100 lysis buffer containing protease and phosphatase inhibitors (2 mM PMSF, 1 mM NaF, 2 mM EDTA, 0.5 mM Na
3VO
4 and 10 μg/mL leupeptin). Cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane (GE Healthcare Life Sciences, Chicago, IL, USA). The membranes were blocked with 5% skim-milk (LPS Solution, Daejeon, Repulic of Korea) for 1 h. The blocked membranes were incubated with primary antibodies (1:1000–2000) at 4 °C overnight followed by horseradish peroxidase-conjugated secondary antibodies (1:5000–10,000) at room temperature for 2 h. The membranes were incubated with ECL reagents (BioMax, Seoul, Republic of Korea) and developed on AGFA CP-BU New X-ray film (Agfa-Gevaert N.V., Mortsel, Belgium). Densitometric and statistical analysis of western blot bands are included in the Supplementary Fig.
5 and
6, and all western blot band images are included in the Supplementary Fig.
7–
13.
Quantitative real-time polymerase chain reaction (qPCR) analysis
Total RNA was extracted using the RNAiso Plus (total RNA extraction reagent; Takara, Shiga, Japan) and cDNA was synthesized using the ReverTra Ace qPCR RT Master Mix (TOYOBO, Osaka, Japan) according to the manufacturer’s protocols. To compare the mRNA expression of target genes, qPCR was performed using the BlasTaq qPCR MasterMix (Applied Biological Materials, Richmond, Canada), and the fluorescent signal of individual target genes was detected using a CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). The qPCR primers used in this study were as follows: PD-L1 forward, 5′- AAATGGAACCTGGCGAAAGC − 3′, and PD-L1 reverse, 5′- GATGAGCCCCTCAGGCATTT -3′; PD-L2 forward, 5′- GTCTTGGGAGCCAGGGTGAC − 3′, and PD-L2 reverse, 5′- TGAAAAGTGCAAATGGCAAGC -3′; GAPDH forward, 5′- CTGACTTCAACAGCGACACC − 3′, and GAPDH reverse, 5′- TAGCCAAATTCGTTGTCATACC − 3′.
Plasmids and small interfering-RNA (si-RNA) transfection
STAT3 was overexpressed with pcDNA3.1-GFP and pcDNA3.1-wild type STAT3-GFP vectors using Lipofectamine 3000 (Invitrogen, Waltham, MA, USA) for 48 h. STAT3 was knocked down with human si-STAT3 (SI02662338; Qiagen, Hilden, Germany) and a negative control si-RNA (1,027,280; Qiagen) using RNAiMax (Invitrogen) for 48 h. Transfection experiments were performed according to the manufacturer’s protocol (
https://www.thermofisher.com).
Immunohistochemistry (IHC)
Human breast tissues, provided by Seoul National University Hospital with approval from the SNUH Institutional Review Board (IRB; IRB No. 1904–141-1029), were fixed in 4% paraformaldehyde for 24 h at 4 °C and embedded in paraffin. The paraffin blocks were cut into 4-μm-thick sections, and the paraffin slides were deparaffinized with xylene and hydrated with graded ethanol. Antigen was unmasked by boiling the sections in 100 mM citrate buffer (pH 6.0) for 10 min and endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 10 min. The slides were blocked in 5% normal goat serum (Vector Laboratories, Burlingame, CA, USA) for 1 h and incubated with primary antibodies (diluted 1:100–200 in antibody diluent solution; Life Technologies, Carlsbad, CA, USA) overnight at 4 °C. The following day, sections were incubated with biotin-conjugated secondary antibodies (diluted 1:100–200 in antibody diluent solution; Vector Laboratories) for 1 h and incubated with avidin-biotin complex reagent for 1 h. The slides were visualized using DAB staining solution (Dako, Santa Clara, CA, USA) followed by counterstaining with hematoxylin solution (Dako). Images of stained sections were obtained using the LAS microscope (Leica Microsystem, Wetzlar, Germany).
Public database analysis
The public datasets used in this study were GSE12276, GSE27830, GSE5460, GSE54002, and GSE36295 (
https://www.ncbi.nlm.nih.gov/geo/). Gene set enrichment analysis (GSEA) was perform to analyze enrichment plots of tumor hallmark gene sets of breast cancer patients (
https://www.gsea-msigdb.org) by dividing the PD-L1 high and low expression groups in the GSE12276, GSE27830 and GSE5460 data sets.
PD-L1 and
LDH-A mRNA expression in human normal breast and breast cancer tissues were comparatively analyzed using the GSE54002 and GSE36295 data sets.
Statistical analysis
Statistical analysis of all data was performed using Microsoft Excel 2016 software (Microsoft Corp., Redmond, WA, USA) and GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). Results are presented as the mean ± standard deviation of at least three independent experiments. Unpaired Student’s t-test was used for analyzing the data, p-values of < 0.05, < 0.01, and < 0.001 were considered statistically significant.
Discussion
Hypoxia, a typical tumor microenvironment, is seen in most solid cancers. In the absence of oxygen, glucose is not completely consumed by oxidative phosphorylation through mitochondria, or by LDH, which produces lactic acid as a byproduct [
2,
4]. In cancer cells, the expression of monocarboxylate transporters (MCTs) such as MCT1 and MCT4, is increased to allow release of the lactic acid that accumulates in cells. When a large amount of lactic acid is released, the extracellular pH is lowered [
21]. Tumor acidosis promotes cancer progression, and various attempts have been made to inhibit this phenomenon, such as inhibiting intracellular LDH-A and lactic acid transporters, and directly administering a pH buffer such as NaHCO
3 [
22‐
24]. In addition, the development of pH-sensitive drug delivery systems to specifically target anti-cancer agents in cancer cells is under investigation [
25]. Neutralizing the acidic pH of cancer cells can inhibit cancer progression, and synergistic effects of neutralization of the acidic pH and treatment with anti-cancer drugs have been reported [
14,
26‐
29]. It is essential to understand the different cancer microenvironments and exploit the effects of cancer acidification.
PD-1 antibodies, such as pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo), as well as PD-L1 antibodies such as atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi), have been approved by the FDA to treat cancer-mediated immune exhaustion [
30]. A synergistic effect of treatment with an immune checkpoint inhibitor and anti-cancer drugs was recently observed, compared with treatment with an immune checkpoint inhibitor alone; clinical trials are currently in progress [
16,
31]. Many new drugs and therapeutic strategies targeting PD-1/PD-L1 are being developed, so it is important to determine the mechanism underlying the increased expression of PD-L1.
Tumors are classified as hot (immunogenic) or cold (non-immunogenic) depending on infiltrated T cells. Hot tumors with infiltrating T cells respond to immunotherapy, whereas cold tumors with little or no infiltrating T cells are resistance to immunotherapy [
32]. Therefore, converting cold tumors into hot tumors can be a very important cancer treatment strategy. In a recent study, most tumors in an acidic environment were characteristic of cold tumors, but infiltered CD8+ T cells were increased when treated with alkaline reagents or pH control gel, which turned cold tumor characteristics into hot tumor characteristics [
33,
34]. In addition, combination therapy of these alkaline reagents and immune checkpoint inhibitor effectively suppressed cancer. Since the progression and development of breast cancer show a positive correlation with acidosis, a good prognosis for immunotherapy can be expected if the acidic tumor microenvironment is targeted to convert the cold tumor characteristics of TNBC into hot tumor characteristics [
35].
The oncogene STAT3, as well as tyrosine kinases such as members of the Janus kinase (JAK) family, are phosphorylated by cytokines or growth factors to sequentially activate STAT3 [
36,
37]. In particular, the phosphorylation of tyrosine 705 of STAT3 induces expression of several target genes that exacerbate cancer progression [
38,
39]. Since STAT3 is also known to induce the expression of PD-L1, it is expected to exert dual effects by inhibiting STAT3 to prevent cancer progression and targeting PD-L1 to prevent immune exhaustion. A clinical trial is currently underway on a combination therapy for metastatic colorectal cancer comprising the STAT3 inhibitor napabucasin and PD-L1 inhibitor pembrolizumab (NCT02851004) [
40]. Targeting STAT3 activation will be important in cancer immunotherapy.
As STAT3, STAT1 is also well known to increase expression of PD-L1. In previous studies, it was reported that IFNs secreted by T cells activate STAT1 to increase the expression of PD-L1 in chronic hepatitis, melanoma and gastric carcinoma [
41‐
43]. When we additionally verified the activation of STAT1 by the acidic tumor microenvironment, the expression of pY-STAT1 was not increased in acidic conditions (Supplementary Fig.
4A). Therefore, we suggested that the increase of PD-L1 by acidosis was increased by activation of STAT3.
In this study, extracellular acidosis increased PD-L1 expression (Fig.
1), as did lactic acid acidification caused by hypoxia or the Warburg effect (the primary cause of tumor acidification in cancer cells) (Fig.
2). The increased expression of PD-L1 induced by acidification was attenuated when the acidic pH was neutralized or buffered (Fig.
3). The increase in PD-L1 expression was due to acidosis-mediated STAT3 activation, and PD-L1 expression did not increase when STAT3 activation was inhibited under acidic conditions in MDA-MB-231 cells (Fig.
4). Moreover, the expression of PD-L1, pY-STAT3, HIF-1α, and LDH-A was higher in breast cancer tissue compared with normal tissue. Overall, our results suggest that extracellular acidosis increases PD-L1 expression via activation of STAT3 in MDA-MB-231 cells.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.